SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053211
Filing Date
2020-11-12
Accepted
2020-11-12 06:16:03
Documents
62
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-10q_20200930.htm 10-Q 2856619
2 EX-31.1 inzy-ex311_9.htm EX-31.1 19436
3 EX-31.2 inzy-ex312_6.htm EX-31.2 19450
4 EX-32.1 inzy-ex321_7.htm EX-32.1 9802
5 EX-32.2 inzy-ex322_8.htm EX-32.2 9854
  Complete submission text file 0001564590-20-053211.txt   8002653

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT inzy-20200930.xml EX-101.INS 1582935
7 XBRL TAXONOMY EXTENSION SCHEMA inzy-20200930.xsd EX-101.SCH 43262
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inzy-20200930_cal.xml EX-101.CAL 40611
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inzy-20200930_def.xml EX-101.DEF 161099
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20200930_lab.xml EX-101.LAB 387752
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20200930_pre.xml EX-101.PRE 295063
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 201303080
SIC: 2834 Pharmaceutical Preparations